PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDanaparoid
Danaparoid sodium
Orgaran (danaparoid sodium) is an unknown pharmaceutical. Danaparoid sodium was first approved as Orgaran on 1996-12-24. It is used to treat pulmonary embolism, thrombocytopenia, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Danaparoid sodium
Tradename
Company
Number
Date
Products
ORGARANAspen GlobalN-020430 DISCN1996-12-24
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
venous thrombosisHP_0004936D020246I82.40
pulmonary embolismHP_0002204D011655I26
thromboembolismHP_0001907D013923—
thrombocytopeniaHP_0001873D013921D69.6
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AB: Heparin group antithrombotic drugs
— B01AB09: Danaparoid
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.6——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDanaparoid sodium
INNdanaparoid sodium
Description
Orgaran (danaparoid sodium) is an unknown pharmaceutical. Danaparoid sodium was first approved as Orgaran on 1996-12-24. It is used to treat pulmonary embolism, thrombocytopenia, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against antithrombin-III.
Classification
Small molecule
Drug classantithrombotics (heparinoid type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID308068-55-5
RxCUI—
ChEMBL IDCHEMBL1201534
ChEBI ID—
PubChem CID—
DrugBankDB06754
UNII ID5004UU3156 (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
462
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Q9UC78
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,360 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
726 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use